LABORATORY CORPORATION OF AMERICA HOLDINGS
Lobbying for LABORATORY CORPORATION OF AMERICA HOLDINGS
Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6209 of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Section 8001 of H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, Pub. L. 119-37, provisions relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; H.R. 6280, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, and H.R. 4559, the Prompt and Fair Pay Act, provisions relating to prompt payment of Medicare Advantage claims; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.